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INTRODUCTION
Antifungal susceptibility tests are performed on
those fungi causing disease, especially if they
belong to a species exhibiting resistance to com-
monly used antifungal agents. Antifungal suscep-
tibility testing is also important for resistance
surveillance, epidemiological studies and for
comparing the in vitro activity of new and
established agents.
Reference methods for antimicrobial suscepti-
bility testing rely on incremental dilution of the
antimicrobial agents to determine the minimum
inhibitory concentrations (MICs) and are mainly
used to establish the activity of a new agent, to
conﬁrm the susceptibility of microorganisms that
yield equivocal results in routine tests, or to
determine their susceptibility when routine tests
are either unreliable or not readily available.
There is also a need for standardized methods
for determining the in vitro susceptibilities of both
new and established antifungal agents against
clinical isolates of ﬁlamentous fungi as there is an
increasing number of agents to choose from for
treating invasive mould disease, and resistance to
antifungal agents in some species has been doc-
umented [1–9].
The Subcommittee on Antifungal Susceptibility
Testing (AFST) of the European Committee for
Antimicrobial Susceptibility Testing (EUCAST)
has developed a broth dilution methodology for
determining the antifungal susceptibility of coni-
dia-forming moulds that cause clinically signiﬁ-
cant invasive fungal disease. This technical note is
based on the EUCAST method and the deﬁnitive
document (E.DEF 9.1) is available in full on the
EUCAST website at http://www.eucast.org.
SCOPE
The standard method described in the deﬁnitive
document provides a valid method for testing
the susceptibility by determining the MICs of
antifungal agents for moulds able to produce
conidia. These MICs show the activity of a
given antifungal drug under deﬁned test
conditions, and can be used for patient
management when other factors, such as
pharmacokinetics, pharmacodynamics and
resistance mechanisms, are taken into account.
The MIC permits moulds to be categorized as
‘‘susceptible’’ (S), ‘‘intermediate’’ (I), or ‘‘resis-
tant’’ (R) to an antifungal drug. In addition,
MIC distributions can be used to deﬁne wild-
type or non-wild-type fungal populations.
The method described in the deﬁnitive
document is intended to provide a valid, easy,
rapid and economic method for testing the
susceptibility of moulds to antifungal agents
and to facilitate an acceptable degree of
conformity, e.g. agreement within speciﬁed
ranges, among laboratories. Since technical
factors are of utmost importance, the standard
focuses on testing conditions including
inoculum preparation and size, the composition
of the growth medium and incubation temper-
ature and duration.
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TEST PROCEDURES
Test procedures are similar to those published in
the document entitled ‘‘Method for the determi-
nation of minimum inhibitory concentration
(MIC) by broth dilution of fermentative yeasts’’
[10]. The medium recommended is RPMI 1640
supplemented with glucose to a ﬁnal concentra-
tion of 2%. The preparation of stock and working
solutions of antifungal agents and the preparation
and storage of microdilution plates is identical to
that described in the method for fermentative
yeasts [10]. However, inoculum preparation is
performed by counting spores in a haemocyto-
meter chamber instead of adjusting the optical
density of the culture using a spectrophotometer
as this would require separate standardization for
each species to compensate for differences in the
size and colour of the spores [11–13]. In addition,
the endpoints are read visually by recording the
degree of growth for each well using a viewing
mirror. Two different endpoints are obtained, the
MIC and the minimum effective concentration
(MEC). The MIC is recorded for polyenes, azoles
and terbinaﬁne whereas the MEC is reserved for
the echinocandins – caspofungin, micafungin and
anidulafungin. The MIC is deﬁned as the lowest
concentration of drug that yields no growth
whereas the MEC is the lowest concentration of
drug that results in macroscopic changes in
ﬁlamentous growth to microcolonies or granular
growth when compared with growth control
wells. Reading the MEC requires a degree of
expertise which can be acquired by examining
under the microscope a small volume removed
from each of the wells of the microdilution plate.
INTERPRETATION OF RESULTS
Interpretation of mould MICs is challenging and
interpretative breakpoints have yet to be estab-
lished. The clinical utility and relevance of testing
moulds also remains uncertain. Most of the
information available is derived from invasive
aspergillosis, which is predominantly caused by
Aspergillus fumigatus.
Amphotericin B
There is no evidence of a clear correlation
between the MIC of amphotericin B and outcome
of treatment [14–16]. The most useful information
is often derived from complete identiﬁcation of
the fungus. Experience indicates that for most
Aspergillus spp., MICs of amphotericin B are
clustered between 0.5 and 2 mg ⁄L. However,
isolates of A. terreus may exhibit higher MICs
[3,17] and, in general, infections due to this
species are associated with a poorer response to
amphotericin B compared with that found for
infections caused by more common species of
Aspergillus [3]. Therefore, high MICs of ampho-
tericin B should be taken into consideration and
alternatives to amphotericin B should be con-
sidered when an invasive fungal disease is due to
A. terreus.
Itraconazole
More is known about the detection of azole
resistance than about a relationship between
MIC and outcome [1,7]. Two isolates were col-
lected from patients who did not respond to
therapy with itraconazole. These isolates were
resistant to itraconazole in a murine model of
invasive aspergillosis and had elevated itraconaz-
ole MICs (MIC ‡ 8 mg ⁄L) [1]. In addition, several
studies have demonstrated that mutations in the
cyp51A gene are associated with high MICs of
itraconazole [2,4–6]. Recently, the itraconazole
wild-type population of A. fumigatus and the
corresponding epidemiological cut-off has been
described [18].
Voriconazole
There is no evident correlation between the MIC
of voriconazole and the outcome of treatment.
However, as some isolates with high MICs of
itraconazole and mutations in the cyp51A gene
also exhibited elevated MICs of voriconazole,
cross resistance cannot be discounted and should
be taken into consideration when choosing ther-
apy [2,4–6]. Recently, the voriconazole wild-type
population of A. fumigatus and the corresponding
epidemiological cut-off has been described [18].
Posaconazole
It is not known whether there is any correlation
between the MIC of posaconazole and the out-
come of treatment. However, as with voriconaz-
ole, isolates with high MICs of itraconazole and
mutations in the cyp51A gene may also exhibit
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elevated MICs of posaconazole, so cross resis-
tance should be considered [2,4–6]. Recently, the
posaconazole wild-type population of A. fumiga-
tus and the corresponding epidemiological cut-off
has been described [18].
Caspofungin
There is no indication of any correlation between
either the MIC or the MEC and outcome of
treatment with caspofungin.
Micafungin
There are no data available to suggest any
correlation between the MIC and outcome of
treatment with micafungin.
QUALITY CONTROL
The deﬁnitive document provides guidelines to
assure the quality of the results by employing
control strains as described in detail by the CLSI
[19].
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